Get started
Author

C. Wilke

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
2020 · H.S. Rugo, F. André, et al. · Annals of Oncology · 192
PDF
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014 · A. Awada, I.N. Bondarenko, et al. · Annals of Oncology · 138
PDF
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
2018 · F. André, E.M. Ciruelos, et al. · Annals of Oncology · 67
Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
2019 · D Juric, E Ciruelos, et al. · Cancer Research · 62
Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors
2017 · D. Sellami, B. Dharan, et al. · Annals of Oncology · 9
PDF
Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1
2019 · H.S. Rugo, F. André, et al. · Annals of Oncology · 5
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
2016 · F. André, B. Kaufman, et al. · Annals of Oncology · 3
PDF
Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial
2019 · S. Loibl, P.F. Conte, et al. · Annals of Oncology · 2
P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC).
2011 · A Awada, IN Bondarenko, et al. · Cancer Research · 2
Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
2017 · F Andre, B Kaufman, et al. · Cancer Research · 1
A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST)
2016 · J. Rodón, G. Curigliano, et al. · Annals of Oncology · 1
PDF
Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study
2025 · K Herrmann, B J Krause, et al. · Nuklearmedizin - NuclearMedicine
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
2016 · H. Iwata, G. Rubovszky, et al. · Annals of Oncology
137TiP A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
2016 · H. Iwata, G. Rubovszky, et al. · Annals of Oncology
Works count: 14
Citation count: 482
H-index: 5
I10-index: 4
Year
Topic
Type